{
    "root": "7f68ffb1-7d79-47ed-afe1-a9489bf42973",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Penicillin G Potassium",
    "value": "20250430",
    "ingredients": [
        {
            "name": "PENICILLIN G POTASSIUM",
            "code": "VL775ZTH4C"
        },
        {
            "name": "NATURAL LATEX RUBBER",
            "code": "2LQ0UUW8IN"
        }
    ],
    "indications": "Therapy: Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. \n                  Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G.\n                  Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued.\n                  \n                     \n                     \n                     \n                        \n                           \n                              \n                                 \n                                    Clinical Indication\n                                 \n                              \n                           \n                           \n                              \n                                 \n                                    Infecting Organism\n                                 \n                              \n                           \n                        \n                        \n                           \n                              Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis \n                           \n                           \n                              \n                                 Streptococcus pyogenes (group A\n                              β-hemolytic streptococcus), other\n                              β-hemolytic streptococci including\n                              groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains)\n                           \n                        \n                        \n                           \n                              Anthrax \n                           \n                           \n                              \n                                 Bacillus anthracis\n                              \n                           \n                        \n                        \n                           \n                              Actinomycosis (cervico-facial disease and thoracic and abdominal disease) \n                           \n                           \n                              \n                                 Actinomyces israelii\n                              \n                           \n                        \n                        \n                           \n                              Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) \n                           \n                           \n                              \n                                 Clostridium species\n                              \n                           \n                        \n                        \n                           \n                              Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) \n                           \n                           \n                              \n                                 Corynebacterium diphtheriae\n                              \n                           \n                        \n                        \n                           \n                              Erysipelothrix endocarditis \n                           \n                           \n                              \n                                 Erysipelothrix rhusiopathiae\n                              \n                           \n                        \n                        \n                           \n                              Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) \n                           \n                           \n                              \n                                 Fusobacterium species and\n                              spirochetes\n                           \n                        \n                        \n                           \n                              Listeria infections including meningitis and endocarditis \n                           \n                           \n                              \n                                 Listeria monocytogenes\n                              \n                           \n                        \n                        \n                           \n                              Pasteurella infections including bacteremia and meningitis \n                           \n                           \n                              \n                                 Pasteurella multocida\n                              \n                           \n                        \n                        \n                           \n                              Haverhill fever \n                           \n                           \n                              \n                                 Streptobacillus moniliformis\n                              \n                           \n                        \n                        \n                           \n                              Rat bite fever \n                           \n                           \n                              \n                                 Spirillum minus or Streptobacillus\n                              \n                              \n                                 moniliformis\n                              \n                           \n                        \n                        \n                           \n                              Disseminated gonococcal infections \n                           \n                           \n                              \n                                 Neisseria gonorrhoeae\n                              \n                              (penicillin-susceptible)\n                           \n                        \n                        \n                           \n                              Syphilis (congenital and neurosyphilis) \n                           \n                           \n                              \n                                 Treponema pallidum\n                              \n                           \n                        \n                        \n                           \n                              Meningococcal meningitis and/or septicemia \n                           \n                           \n                              \n                                 Neisseria meningitidis\n                              \n                           \n                        \n                        \n                           \n                              Gram-negative bacillary infections (bacteremias)\n                              \n                                 Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections.\n                           \n                           \n                              \n                                 Gram-negative bacillary organisms (i.e. Enterobacteriaceae)\n                              \n                           \n                        \n                     \n                  \n                  To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.",
    "contraindications": "Penicillin G Potassium for Injection, USP may be given intravenously or intramuscularly. The usual dose recommendations are as follows:",
    "warningsAndPrecautions": "Penicillin G Potassium for Injection, USP is supplied in dry powder form in vials containing 1,000,000 units (1 million units), 5,000,000 units (5 million units) or 20,000,000 units (20 million units) of crystalline penicillin G as the potassium salt, buffered with sodium citrate to an optimum pH. Each million units contains approximately 6.9 milligrams of sodium (0.3 mEq) and 65.8 milligrams of potassium (1.68 mEq).\n                  \n                     \n                     \n                     \n                     \n                        \n                           \n                              NDC 44567-310-10\n                           \n                           \n                               1,000,000 units (1 million units) vial\n                           \n                           \n                              (carton of 10)\n                           \n                        \n                        \n                           \n                              NDC 44567-311-10\n                           \n                           \n                               5,000,000 units (5 million units) vial \n                           \n                           \n                              (carton of 10)\n                           \n                        \n                        \n                           \n                              NDC 44567-312-01\n                           \n                           \n                              20,000,000 units (20 million units) vial \n                           \n                           \n                              (carton of 1)\n                           \n                        \n                        \n                           \n                              NDC 44567-312-10\n                           \n                           \n                               20,000,000 units (20 million units) vial \n                           \n                           \n                              (carton of 10)\n                           \n                        \n                     \n                  \n                  \n                     Store the dry powder at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].\n                  \n                  \n                     Sterile constituted solution may be kept in refrigerator 2° to 8°C (36° to 46°F) for 7 days without significant loss of potency.\n                  \n                  Clinitest is a registered trademark of Miles, Inc.\n                  Clinistix is a registered trademark of Bayer Corporation.\n                  Tes-Tape is a registered trademark of Eli Lilly Company.\n                  Manufactured for:\n                  \n                     WG Critical Care, LLC\n                  \n                  Paramus, NJ 07652\n                  Rev: 09/2024",
    "adverseReactions": "A history of a hypersensitivity (anaphylactic) reaction to any penicillin is a contraindication."
}